210 related articles for article (PubMed ID: 29397576)
1. Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India.
McGettigan P; Roderick P; Kadam A; Pollock A
Br J Clin Pharmacol; 2019 Jan; 85(1):59-70. PubMed ID: 29397576
[TBL] [Abstract][Full Text] [Related]
2. Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs.
McGettigan P; Roderick P; Mahajan R; Kadam A; Pollock AM
PLoS Med; 2015 May; 12(5):e1001826; discussion e1001826. PubMed ID: 25965416
[TBL] [Abstract][Full Text] [Related]
3. Regulatory enforcement of the marketing of fixed-dose combinations in India: a case study of systemic antibiotics.
Brhlikova P; Mehta A; McGettigan P; Pollock AM; Roderick P; Farooqui HH
J Pharm Policy Pract; 2023 Nov; 16(1):139. PubMed ID: 37950272
[TBL] [Abstract][Full Text] [Related]
4. Fixed dose combinations of anti-tubercular, antimalarial and antiretroviral medicines on the Indian market: critical analysis of ubiquity, sales and regulatory status.
Ligade VS; Thakar TM; Dengale SJ
Trop Med Int Health; 2019 Feb; 24(2):238-246. PubMed ID: 30422371
[TBL] [Abstract][Full Text] [Related]
5. High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries.
Bortone B; Jackson C; Hsia Y; Bielicki J; Magrini N; Sharland M
PLoS One; 2021; 16(1):e0241899. PubMed ID: 33471786
[TBL] [Abstract][Full Text] [Related]
6. Consumption of systemic antibiotics in India in 2019.
Koya SF; Ganesh S; Selvaraj S; Wirtz VJ; Galea S; Rockers PC
Lancet Reg Health Southeast Asia; 2022 Sep; 4():100025. PubMed ID: 37383993
[TBL] [Abstract][Full Text] [Related]
7. Assessment of rationality of available fixed dose combinations of antibiotics in India.
Anand P; Kaur N; Verma V; Shafiq N; Malhotra S
Expert Rev Anti Infect Ther; 2022 May; 20(5):797-808. PubMed ID: 34865581
[TBL] [Abstract][Full Text] [Related]
8. Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India.
Evans V; Roderick P; Pollock AM
BMJ Glob Health; 2018; 3(2):e000263. PubMed ID: 29527355
[TBL] [Abstract][Full Text] [Related]
9. Systemic antibiotic sales and WHO recommendations, India.
Mehta A; Brhlikova P; McGettigan P; Pollock AM; Roderick P; Farooqui HH
Bull World Health Organ; 2022 Oct; 100(10):610-619. PubMed ID: 36188020
[TBL] [Abstract][Full Text] [Related]
10. India's ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?
Sulis G; Pradhan R; Kotwani A; Gandra S
J Pharm Policy Pract; 2022 Apr; 15(1):33. PubMed ID: 35484606
[TBL] [Abstract][Full Text] [Related]
11. Estimating the Impact of Food and Drug Administration's Unapproved Drug Initiative on Drug Prices and Sales.
Sharma D; Schumock GT; Saffore CD; Albert Edwards S; Walton SM
Ther Innov Regul Sci; 2020 Mar; 54(2):424-430. PubMed ID: 32072591
[TBL] [Abstract][Full Text] [Related]
12. Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis.
Sulis G; Batomen B; Kotwani A; Pai M; Gandra S
PLoS Med; 2021 Jul; 18(7):e1003682. PubMed ID: 34197449
[TBL] [Abstract][Full Text] [Related]
13. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries.
Hsia Y; Sharland M; Jackson C; Wong ICK; Magrini N; Bielicki JA
Lancet Infect Dis; 2019 Jan; 19(1):67-75. PubMed ID: 30522834
[TBL] [Abstract][Full Text] [Related]
14. Fixed-dose combinations banned in India: is it the right decision? An eye-opening review.
Miranda MRH; Dubey A; G S R; Charyulu RN
Expert Opin Drug Saf; 2019 Oct; 18(10):977-985. PubMed ID: 31374180
[No Abstract] [Full Text] [Related]
15. Global sales of oral antibiotics formulated for children.
Li G; Jackson C; Bielicki J; Ellis S; Hsia Y; Sharland M
Bull World Health Organ; 2020 Jul; 98(7):458-466. PubMed ID: 32742031
[TBL] [Abstract][Full Text] [Related]
16. Over-the-counter sales of antibiotics from community pharmacies in Abu Dhabi.
Dameh M; Green J; Norris P
Pharm World Sci; 2010 Oct; 32(5):643-50. PubMed ID: 20640511
[TBL] [Abstract][Full Text] [Related]
17. Critical Analysis of Cardiovascular and Central Nervous System Fixed Dose Combinations Available in Indian Market.
Prajapati K; Shah S; Desai M
J Clin Diagn Res; 2016 Dec; 10(12):FC36-FC39. PubMed ID: 28149832
[TBL] [Abstract][Full Text] [Related]
18. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
Ostroff C; Lee CE; McMeekin J
Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
[TBL] [Abstract][Full Text] [Related]
19. Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data.
Farooqui HH; Selvaraj S; Mehta A; Heymann DL
PLoS One; 2018; 13(10):e0204805. PubMed ID: 30332450
[TBL] [Abstract][Full Text] [Related]
20. Introduction and geographic availability of new antibiotics approved between 1999 and 2014.
Kållberg C; Årdal C; Salvesen Blix H; Klein E; M Martinez E; Lindbæk M; Outterson K; Røttingen JA; Laxminarayan R
PLoS One; 2018; 13(10):e0205166. PubMed ID: 30325963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
